Views: 0 Author: Site Editor Publish Time: 2026-07-03 Origin: Site
News Release – July 3, 2026
In January 2025, ICH officially finalised E6(R3), marking a new revision cycle for the GCP guidelines. Building on that, ICH further released Annex 2, which provides supplementary GCP considerations for clinical trials incorporating decentralised elements, pragmatic elements, and/or real‑world data (RWD).
The release of this annex essentially responds to fundamental changes in clinical trial models in recent years: trials are no longer confined to traditional investigative sites. Remote visits, home healthcare, digital health technologies (DHT), and the widespread use of real‑world data are reshaping the operational boundaries of clinical research.
2.1 Decentralised Elements: Trial Activities Move Beyond Investigative Sites
Decentralised elements refer to trial‑related activities conducted outside the investigator’s location, including:
Trial follow‑up visits at subjects' homes, local medical centres, or mobile health units
Remote data collection using digital health technologies (DHT)
Implementation of remote informed consent
This breaks the physical boundaries of trials, but at the same time imposes higher requirements on the standardisation of data collection and subject protection.
2.2 Pragmatic Elements: Integration of Clinical Trials with Routine Medical Practice
Pragmatic elements involve incorporating aspects of routine clinical practice into trial design and conduct, for example by streamlining data collection processes to simplify protocols. The core value of such designs is that trial results more closely reflect real‑world clinical scenarios and offer greater generalisability.
2.3 Real‑World Data: Diversification of Data Sources
Annex 2 clearly distinguishes two types of trial data:
Primary data: generated specifically for the trial
Secondary data: obtained from external sources outside the trial (e.g., electronic health records, disease registries, claims data)
RWD can be used as endpoints, outcomes, or external controls, but its fitness‑for‑purpose, quality, and governance framework become critical responsibilities of the sponsor.
3.1 IRB/IEC: Privacy and Data Security Become Key Focus Areas
Ethics committees need to pay special attention to:
Subject privacy protection
Data security risks
Compliance of remote informed consent
Safeguarding subject rights in decentralised scenarios
3.2 Investigators: Tiered Oversight and Remote Management
Investigator responsibilities expand to include:
Managing investigational products remotely or locally
Implementing tiered oversight to ensure control over decentralised activities
Adapting to new changes in the trial product supply chain
3.3 Sponsors: Data Governance Framework and Multi‑party Collaboration
Sponsors assume more systematic responsibilities:
Ensuring the fitness‑for‑purpose of RWD
Establishing a comprehensive data governance framework
Clarifying multi‑party collaboration responsibilities
Engaging in early dialogue with regulatory authorities
4.1 The Principle of Proportionality Runs Throughout
Annex 2 emphasises that trial design and technology application should be based on the risk‑proportionality principle – the higher the risk, the tighter the controls. This requires sponsors to systematically assess potential risks at the design stage rather than remediating after the fact.
4.2 Quality by Design (QbD) Becomes the Underlying Logic
Regardless of the operational methods and data sources used, the QbD approach should be applied to ensure that design elements, DHT, and data sources align with the trial objectives. This is an extension of the principles in Annex 1 and serves as the methodological foundation of Annex 2.
4.3 Patient Engagement is Brought Forward
The guidance advises applicants to involve patients and patient organisations early in the trial design phase to ensure the suitability of wearables, remote collection tools, etc. This marks a substantive shift from a "research‑centric" to a "patient‑centric" approach in clinical trial design.
4.4 Regulatory Communication is Advanced
Annex 2 repeatedly stresses the need for early communication with regulatory authorities. For trials employing decentralisation or RWD, confirming design compliance with agencies such as the FDA and NMPA in advance has become a key pathway to reducing rework risks later.
5.1 New Directions for Capability Building
Annex 2 calls for capability upgrades among CROs and sponsors: remote monitoring, application of digital health technologies, RWD governance, and cross‑geographical supply chain management – all areas that were less covered under the traditional GCP framework.
5.2 Rebalancing of Compliance Costs
In the short term, establishing systems that meet Annex 2 requirements requires investment – data governance frameworks, remote informed consent processes, and privacy protection mechanisms. However, in the long run, decentralised trials can reduce patient recruitment costs and improve adherence, reshaping the cost structure.
5.3 Opportunities for International Collaboration
The globally harmonised nature of ICH guidelines means that Chinese CROs that can establish systems compliant with E6(R3) Annex 2 early will have a first‑mover advantage in undertaking multinational trials and serving drug companies going global.
The release of ICH E6(R3) Annex 2 is essentially a formal response of the GCP framework to the trends of digitalisation, decentralisation, and data diversification in clinical trials. It is not a negation of traditional GCP, but rather provides a compliance framework for novel trial models under the risk‑proportionality principle.
For the CRO industry, this is both a challenge for capability enhancement and an opportunity to reshape the competitive landscape. Organisations that can swiftly build service systems aligned with Annex 2, possess RWD governance capabilities, and excel in digital trial execution will be better positioned in the next round of industry consolidation.
